中兵紅箭(000519.SZ):約4.5884億股限售股將解禁
格隆匯2月23日丨中兵紅箭(000519.SZ)公佈,此次豫西工業集團有限公司申請解除的公司2013年度重大資產重組限售流通股份數量約2.4092億股,佔公司股份總數的17.3008%。
同日,豫西工業集團有限公司、中兵投資管理有限責任公司、吉林江北機械製造有限責任公司、山東特種工業集團有限公司申請解除的中兵紅箭股份有限公司2016年度重大資產重組暨募集配套資金限售流通股份數量約2.1792億股,佔公司股份總數的15.6490%。
以上兩次重大資產重組申請解除限售流通股份數量合計約4.5884億股,佔公司股份總數的32.9498%。
此次限售流通股份的可上市流通日期為2020年2月26日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.